These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 33852242)

  • 1. Treatment of Impetigo and Antimicrobial Resistance.
    Schachner LA; Lynde CW; Kircik LH; Torrelo A; Hohl D; Kwong P; Oza V; Andriessen A; Hebert AA
    J Drugs Dermatol; 2021 Apr; 20(4):366-372. PubMed ID: 33852242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
    Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
    J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
    Schachner LA; Andriessen A; Benjamin LT; Claro C; Eichenfield LF; Esposito SM; Keller L; Kircik L; Kwong PC; McCuaig C
    J Drugs Dermatol; 2021 Feb; 20(2):134-142. PubMed ID: 33538559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ozenoxacin: a review of preclinical and clinical efficacy.
    Vila J; Hebert AA; Torrelo A; López Y; Tato M; García-Castillo M; Cantón R
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):159-168. PubMed ID: 30686133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions.
    Schachner LA; Torrelo A; Grada A; Micali G; Kwong PC; Scott GB; Benjamin L; Gonzalez ME; Andriessen A; Eberlein T; Eichenfield LF
    J Drugs Dermatol; 2020 Mar; 19(3):281-290. PubMed ID: 32550690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozenoxacin: A Novel Topical Quinolone for Impetigo.
    Wren C; Bell E; Eiland LS
    Ann Pharmacother; 2018 Dec; 52(12):1233-1237. PubMed ID: 29962213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.
    Sahu JK; Mishra AK
    Curr Drug Discov Technol; 2019; 16(3):259-264. PubMed ID: 29732990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus.
    Tarragó C; Esquirol LP; Arañó A; Lachamp L; D'Aniello F; Zsolt I
    Future Microbiol; 2018 May; 13():21-30. PubMed ID: 29745240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
    Rosen T; Albareda N; Rosenberg N; Alonso FG; Roth S; Zsolt I; Hebert AA
    JAMA Dermatol; 2018 Jul; 154(7):806-813. PubMed ID: 29898217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the antibacterial activity of ozenoxacin.
    Canton R; Chouinard L; Tarragó C
    Future Microbiol; 2018 May; 13():1-2. PubMed ID: 29745241
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
    Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
    Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials.
    Hebert AA; Albareda N; Rosen T; Torrelo A; Grimalt R; Rosenberg N; Zsolt I; Masramon X
    J Drugs Dermatol; 2018 Oct; 17(10):1051-1057. PubMed ID: 30365584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International comparison of guidelines for management of impetigo: a systematic review.
    Hall LM; Gorges HJ; van Driel M; Magin P; Francis N; Heal CF
    Fam Pract; 2022 Jan; 39(1):150-158. PubMed ID: 34184743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ozenoxacin 1% cream (Xepi) for impetigo.
    Med Lett Drugs Ther; 2019 Apr; 61(1570):63-64. PubMed ID: 31169810
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparative review of current topical antibiotics for impetigo.
    Galindo E; Hebert AA
    Expert Opin Drug Saf; 2021 Jun; 20(6):677-683. PubMed ID: 33726585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic stewardship in skin infections: a cross-sectional analysis of early-career GP's management of impetigo.
    Heal C; Gorges H; van Driel ML; Tapley A; Davis J; Davey A; Holliday L; Ball J; Najib N; Spike N; FitzGerald K; Magin P
    BMJ Open; 2019 Oct; 9(10):e031527. PubMed ID: 31662391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ozenoxacin Cream, 1% - Topical Treatment of Impetigo.
    Gupta AK; Versteeg SG; Abramovits W
    Skinmed; 2017; 15(1):57-59. PubMed ID: 28270312
    [No Abstract]   [Full Text] [Related]  

  • 18. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
    Torrelo A; Grimalt R; Masramon X; Albareda López N; Zsolt I
    Dermatology; 2020; 236(3):199-207. PubMed ID: 31958794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QbD Based Formulation Development and Optimisation of Ozenoxacin Topical Nano-Emulgel and Efficacy Evaluation Using Impetigo Mice Model.
    Ramireddy AR; Behara DK
    AAPS PharmSciTech; 2024 Apr; 25(5):90. PubMed ID: 38649513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.